Cited 7 times in
Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박민수 | - |
dc.date.accessioned | 2017-10-26T07:18:51Z | - |
dc.date.available | 2017-10-26T07:18:51Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 1042-8194 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/151869 | - |
dc.description.abstract | A fixed dose regimen for tyrosine kinase inhibitors (TKIs) is postulated to be responsible for variable safety outcomes in the treatment of chronic myelogenous leukemia (CML). The objective of this study was to explore an optimal dosing regimen for a TKI, radotinib, to improve its safety profile. Clinical data were obtained from a Phase 2 study of fixed-dose radotinib in 77 Asian patients with CML. The magnitude of radotinib dose adjusted for patient's body weight (Dose/BW) and the probability of dose-limiting toxicity (DLT) demonstrated a positive association (Logit[P]?=?0.86*[Dose/BW]-4.45, p?=?0.001). There was a significant difference in the Kaplan-Meier curves for time to first DLT between the patient subgroups of Dose/BW?<6 and?≥6?mg/kg (259 versus 83 days). Consequently, a two-tier weight-based dosing regimen may improve the safety of radotinib: 300?mg or 400?mg twice daily for patients weighing?≤65 or?>65?kg, respectively. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Informa Healthcare | - |
dc.relation.isPartOf | LEUKEMIA & LYMPHOMA | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Agents/pharmacology* | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use | - |
dc.subject.MESH | Asian Continental Ancestry Group | - |
dc.subject.MESH | Benzamides/pharmacology* | - |
dc.subject.MESH | Benzamides/therapeutic use | - |
dc.subject.MESH | Body Surface Area | - |
dc.subject.MESH | Body Weight | - |
dc.subject.MESH | Dose-Response Relationship, Drug | - |
dc.subject.MESH | Drug Dosage Calculations | - |
dc.subject.MESH | Drug Resistance, Neoplasm | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fusion Proteins, bcr-abl/antagonists & inhibitors* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Imatinib Mesylate/pharmacology | - |
dc.subject.MESH | Imatinib Mesylate/therapeutic use | - |
dc.subject.MESH | Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy* | - |
dc.subject.MESH | Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Philadelphia Chromosome | - |
dc.subject.MESH | Protein Kinase Inhibitors/pharmacology* | - |
dc.subject.MESH | Protein Kinase Inhibitors/therapeutic use | - |
dc.subject.MESH | Pyrazines/pharmacology* | - |
dc.subject.MESH | Pyrazines/therapeutic use | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Young Adult | - |
dc.title | Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses | - |
dc.type | Article | - |
dc.publisher.location | England | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Pediatrics | - |
dc.contributor.googleauthor | Hayeon Noh | - |
dc.contributor.googleauthor | Min Soo Park | - |
dc.contributor.googleauthor | Sung-Hyun Kim | - |
dc.contributor.googleauthor | Suk Joong Oh | - |
dc.contributor.googleauthor | Dae Young Zang | - |
dc.contributor.googleauthor | Hye Lin Park | - |
dc.contributor.googleauthor | Dae Jin Cho | - |
dc.contributor.googleauthor | Dong-Wook Kim | - |
dc.contributor.googleauthor | Jangik I. Lee | - |
dc.identifier.doi | 10.3109/10428194.2015.1113278 | - |
dc.contributor.localId | A01468 | - |
dc.relation.journalcode | J02165 | - |
dc.identifier.eissn | 1029-2403 | - |
dc.identifier.pmid | 26666371 | - |
dc.identifier.url | http://www.tandfonline.com/doi/full/10.3109/10428194.2015.1113278 | - |
dc.subject.keyword | Radotinib | - |
dc.subject.keyword | chronic myelogenous leukemia | - |
dc.subject.keyword | dose optimization | - |
dc.subject.keyword | dose-response relationship | - |
dc.subject.keyword | tyrosine kinase inhibitor | - |
dc.subject.keyword | weight-based dosing | - |
dc.contributor.alternativeName | Park, Min Soo | - |
dc.contributor.affiliatedAuthor | Park, Min Soo | - |
dc.citation.volume | 57 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 1856 | - |
dc.citation.endPage | 1864 | - |
dc.identifier.bibliographicCitation | LEUKEMIA & LYMPHOMA, Vol.57(8) : 1856-1864, 2016 | - |
dc.date.modified | 2017-10-24 | - |
dc.identifier.rimsid | 46194 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.